- Hoth Therapeutics Inc HOTH announced that HT-ALZ, a therapeutic in development for Alzheimer's disease, achieved positive preclinical results that outpaced its previous study.
- The company said the higher dose appears to be most beneficial in a spatial memory test performed at Washington University in St Louis.
- Hoth has now completed the behavior results for Locomotor Activity/Exploratory Behavior, Elevated Plus Maze, Spatial Navigation Water Maze, Prepulse Inhibition of Startle, and Conditioned Fear and looks forward to sharing further data as it becomes available.
- "We now will begin processing the brains of the animal subjects for total plaque load and soluble/insoluble beta-amyloid levels," said Robb Knie, CEO of Hoth Therapeutics.
- Previously Hoth reported study results focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Aβ in the brain interstitial fluid using an established Alzheimer's Disease mouse model (aged APP/PS1+/- mice).
- The initial data from those studies showed a significant decrease in Aβ in both male and female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aβ levels.
- Earlier this year, Hoth Therapeutics announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model.
- The data supports the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ.
- Price Action: HOTH shares are up 78.70% at $3.36 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
